Clinical trials: Hepatobiliary Diseases
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
Metabolic Disease, Fatty Liver, Nonalcoholic
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
Given the current increase in the incidence of dyslipidemia and obesity in the general population, there is a strong interest in identifying dietary factors capable of preventing the onset of metabolic diseases or at least…
- Trial name
- NCT05558592
- Testing
- Dietary supplementation with fresh oranges, Balanced Diet without oranges
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Cholestasis, Liver Disease
Compassionate Use of Omegaven IV Fat Emulsion
This protocol involves the compassionate use of intravenous fish oil infusion, Omegaven. The protocol involves infants and children with parenteral nutrition-associated liver disease to enable the reversal of elevated serum liver…
- Trial name
- NCT02477345
- Testing
- Omegaven IV
- Where
- United States
- Sponsor
- Northwell Health
Surgery, Obesity
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
The aim of the study is to demonstrate the superiority of bariatric surgery on the disappearance of NASH without worsening of fibrosis in comparison to medical standard treatment in obese patients (35 kg/m² > BMI ≥ 30 kg/m²) with…
- Conditions
- Surgery, Obesity, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NASHSURG (NCT03472157)
- Testing
- Lifestyle therapy, Bariatric surgery
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Liver Steatoses
Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )
the goal of this study (observational study ) is to learn about the subclinical cardiovascular changes in patients with nonalcoholic fatty liver . the main questions it aims to answer are 1.
- Trial name
- NCT05790057
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Primary Sclerosing Cholangitis
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC), although uncommon, is a devastating and insidiously progressive liver disease, resulting from advancing inflammation, fibrosis and obliteration of the bile ducts in the liver, leading to…
- Trial name
- NCT01088607
- Testing
- ursodeoxycholic acid (UDCA)
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Tennessee
Patient Survival, Graft Survival
Donor and Recipient Mismatch in Liver Transplantation
This observational study aims to investigate the impact of gender disparity between donors and recipients on long-term outcomes after liver transplantation (LT).
- Conditions
- Patient Survival, Graft Survival, Liver Disease (Alcoholic or Not), Liver Transplant Surgery
- Trial name
- DR-MM in LT (NCT07250919)
- Where
- Canada
- Volunteers
- 1,146 people
- Sponsor
- University of Jena
COVID-19, Liver Disease
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal.
- Conditions
- COVID-19, Liver Disease, Vaccine Reaction
- Trial name
- NCT04883177
- Where
- 37 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatitis C
The Dublin Zepatier Study
Evaluation of Zepatier in a community-based setting among cirrhotic and non-cirrhotic patients on stable opiate substitution therapy.
- Trial name
- NCT02895958
- Testing
- Zepatier
- Where
- Ireland
- Volunteers
- 3 people
- Sponsor
- Mater Misericordiae University Hospital
Autoimmune Liver Disease
Patterns and Outcome of Autoimmune Related Liver Disease
Study of the different patterns of autoimmune related chronic liver disease to assess the prevalence of various types and outcome of treatment of autoimmune related chronic liver disease
- Trial name
- NCT03898414
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non-alcoholic Steatohepatitis
Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis
Patients with non-alcoholic fatty liver disease (NAFLD) are at increased risk of more aggressive liver disease; non-alcoholic steatohepatitis (NASH) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and…
- Trial name
- NCT05254626
- Testing
- Dapagliflozin 10Mg Tab, Pioglitazone 30 mg
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Chronic Liver Disease
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
Chronic liver diseases (CLDs) represent a major worldwide public health burden. Worldwide estimations show that 844 million people have CLDs, a lot more than other chronic diseases such as diabetes or cardiovascular diseases.
- Trial name
- NCT03704792
- Testing
- FibroScan 530 Compact
- Where
- 5 sites in France
- Volunteers
- 207 people
- Sponsor
- Echosens
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.
- Conditions
- Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- EMMINENCE (NCT02784444)
- Testing
- MSDC-0602K
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Cirius Therapeutics, Inc.
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Alcoholism, Alcohol Use Disorder
Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.
Investigator seeks to determine wether integrating an addiction team into a liver transplantation unit improves the prognosis of patients with alcohol-related liver disease requiring liver transplantation.
- Conditions
- Alcoholism, Alcohol Use Disorder, Alcohol; Liver
- Trial name
- NCT04964687
- Testing
- Liver transplantation
- Where
- France
- Volunteers
- 616 people
- Sponsor
- University Hospital, Montpellier
Non-Alcoholic Fatty Liver Disease
Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
The study was performed on 160 participants, to ensure the impact of multi vitamin and mineral to reduce NAFLD
- Trial name
- NCT05897606
- Testing
- Multiviamins and minerals
- Where
- Iraq
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Sulaimani Polytechnic University
Metabolic Syndrome, Obesity
Potential Beneficial Effects of Resveratrol
We want to investigate whether the food supplement resveratrol is able to counteract the detrimental effects of obesity.
- Trial name
- NCT01150955
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK…
- Trial name
- HI (NCT02891408)
- Testing
- Firsocostat, Fenofibrate
- Where
- 5 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Liver Disease, Thrombocytopenia
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
The primary purpose of this study is to compare the efficacy of lusutrombopag with placebo for the treatment of thrombocytopenia in patients with chronic liver disease who are undergoing elective invasive procedures.
- Trial name
- L-PLUS 2 (NCT02389621)
- Testing
- Lusutrombopag
- Volunteers
- 215 people
- Sponsor
- Shionogi
Carcinoma, Hepatocellular
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
- Trial name
- NCT03289533
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.